ASP2535
Jump to navigation
Jump to search
| Names | |
|---|---|
| IUPAC name
4-[3-(6-phenylpyridin-3-yl)-5-propan-2-yl-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ECHA InfoCard | Lua error in Module:Wikidata at line 880: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 880: attempt to index field 'wikibase' (a nil value).Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| E number | Lua error in Module:Wikidata at line 880: attempt to index field 'wikibase' (a nil value). |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C22H18N6O | |
| Molar mass | 382.427 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
ASP2535 is an inhibitor of the type 1 glycine transporter.[1] It could potentially be used in treatment of Alzheimer's disease and schizophrenia.
Potential uses
[edit | edit source]ASP2535 has been investigated for the treatment of Alzheimer's disease and schizophrenia, it is able to inhibit the memory deficit induced by scopolamine, an anticholinergic agent.[1]
References
[edit | edit source]
